Published in Eur J Clin Pharmacol on September 16, 2015
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation (2005) 2.23
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation (2010) 1.96
Clinical evaluation of perhexiline maleate in patients with angina pectoris. Br Med J (1971) 1.60
Peripheral and autonomic neuropathy after treatment with perhexiline maleate. Br Med J (1977) 1.42
Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol (1996) 1.22
[Letter: Peripheral neuropathy after prolonged adsorption of perhexiline maleate. 2 cases]. Nouv Presse Med (1975) 1.20
Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol (1978) 1.18
Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation (1990) 1.12
Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet (1984) 1.11
Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics. Int J Cardiol (1986) 1.10
Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol (2002) 0.98
Ultrastructure of the atrial, ventricular, and Purkinje cell, with special reference to the genesis of arrhythmias. Circulation (1973) 0.97
Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology (1994) 0.95
Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit (1996) 0.92
Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease. Heart (2010) 0.90
Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics (2003) 0.88
Effect of Ca2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro. Arzneimittelforschung (1981) 0.87
Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.86
Stereoselective pharmacokinetics of perhexiline. Xenobiotica (1986) 0.82
Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br J Pharmacol (1985) 0.81
Myocardial uptake of drugs and clinical effects. Clin Pharmacokinet (1987) 0.80
CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos (2006) 0.80
The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. Br J Clin Pharmacol (2006) 0.79
Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake. Br J Clin Pharmacol (2014) 0.79
The effect of perhexiline on myocardial protection during coronary artery surgery: a two-centre, randomized, double-blind, placebo-controlled trial. Eur J Cardiothorac Surg (2014) 0.78
Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes. Intern Med J (2004) 0.78
Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline. Ther Drug Monit (2011) 0.78
[Slow and incomplete regression of peripheral neuropathy due to perhexiline maleate]. Ann Cardiol Angeiol (Paris) (1977) 0.78
Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris. Eur J Pharmacol (2007) 0.77
Clinical trial of a new antianginal drug: perhexiline maleate. J Clin Pharmacol New Drugs (1972) 0.77